Corcept Therapeutics (CORT) shares are climbing Friday after the company released promising data from its Phase 2 DAZALS study for amyotrophic lateral sclerosis (ALS). The study showed that patients taking 300 mg of dazucorilant daily had an 87% lower risk of death compared to those on a placebo. That's a big deal for a disease that currently has very limited treatment options.

ALS, often called Lou Gehrig's disease, is a progressive neurodegenerative condition that destroys motor neurons in the brain and spinal cord. It leads to muscle loss, paralysis, and eventually respiratory failure. So any drug that can meaningfully extend survival is noteworthy.

Survival Benefit Despite Missed Primary Endpoint

Here's where it gets a bit nuanced. The DAZALS study didn't hit its primary endpoint at the end of the 24-week treatment period. But even so, patients on the 300 mg dose showed improved overall survival. That finding is consistent with an earlier 84% reduction in death risk seen after one year of treatment.

The survival benefit held up over the longer term. For patients who stayed on 300 mg of dazucorilant for more than 24 weeks—either in the main study or in the long-term extension phase—the reduction in risk of death was 64% at one year and 61% at two years, compared to patients who got placebo or a lower dose and didn't receive dazucorilant in the extension.

So while the study didn't check every box on the primary endpoint, the survival data is compelling. It's the kind of result that can move a stock—and it did.

Earnings Miss and Revenue Shortfall

Not everything was rosy this quarter. Corcept reported a loss of $0.30 per share, missing the consensus estimate of a $0.16 loss. Revenue came in at $164.9 million, also below the $192.51 million analysts were expecting.

But the company did raise its fiscal 2026 sales guidance on Thursday, from $900 million–$1 billion to $950 million–$1.05 billion. That new range is above the consensus of $941.18 million, which suggests management sees stronger sales ahead.

How Corcept Ranks on Value, Quality, and Momentum

If you're looking at Corcept through a quantitative lens, the picture is mixed. According to the MarketDash Edge scorecard, the company scores poorly on value (19.85 out of 100), meaning the stock trades at a steep premium relative to peers. Momentum is also weak at 7.93, indicating the stock has been underperforming the broader market. But quality is strong at 80.22, reflecting a healthy balance sheet.

The verdict? Corcept has a solid foundation, but the stock may struggle to sustain upward momentum without broader market support or continued positive news flow.

Price Action

Corcept shares were up 3.37% at $48.09 at the time of publication Friday. The market is clearly cheering the ALS data, but the earnings miss and weak momentum scores suggest investors should keep an eye on the bigger picture.